Vaccines against respiratory syncytial virus: The time has finally come.
Vaccines against respiratory syncytial virus: The time has finally come.
复制标题
DOI：
10.1016/j.vaccine.2016.04.083
复制
发表时间：
2016-06-24
期刊：
影响因子：
5.5
通讯作者：
Graham BS
中科院分区：
文献类型：
--
作者：
Graham BS
呼吸道合胞病毒造成重大的公共卫生负担，特别是在幼儿和虚弱的老年人中。整个福尔马林灭活的RSV疫苗留下的增强型RSV病(ERD)的遗留问题，以及病毒和新生儿的复杂生物学，推迟了有效疫苗的开发。然而，对ERD相关因素的新见解以及在理解融合(F)糖蛋白的抗原结构方面的突破增加了人们对疫苗开发可能的乐观情绪。这导致了行业、监管机构、政府和非营利组织投入时间和资源来开发必要的基础设施，使RSV候选疫苗的高级临床开发成为现实。
Respiratory syncytial virus causes a significant public health burden, particularly in very young infants and the frail elderly. The legacy of enhanced RSV disease (ERD) from a whole formalin-inactivated RSV vaccine, and the complex biology of the virus and the neonate have delayed the development of effective vaccines. However, new insights into factors associated with ERD and breakthroughs in understanding the antigenic structure of the fusion (F) glycoprotein have increased optimism that vaccine development is possible. This has led to investment of time and resources by industry, regulatory authorities, governments, and nonprofit organizations to develop the infrastructure needed to make the advanced clinical development of RSV vaccine candidates a reality.